Study of new therapies for Crohn's and colitis
Part of Digestive system clinical trials.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Crohn's disease or ulcerative colitis, confirmed by a scope and tissue sample.
- Your disease must be moderate to severe, as measured by your doctor using standard scoring tools.
- You need to be on stable doses of any current IBD medications for a certain period before the study.
- You cannot have certain complications like an active abscess, a stoma, or extensive bowel surgery in the past.
- If you have ulcerative colitis, you cannot have recently had a severe flare called toxic megacolon or needed IV steroids in the last 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This trial tests a new treatment called CMTS0929 for people with inflammatory bowel disease (IBD), a condition that causes inflammation in the digestive tract. It aims to see if the treatment works and is safe.
This study tests an experimental tablet for people with moderate to severe ulcerative colitis that hasn't improved with standard treatments. It aims to see if the tablet can reduce symptoms and inflammation.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study tests an investigational drug called MB-001 for people with moderate to severe ulcerative colitis who have already tried standard treatments without success. It aims to see if the drug is safe and helps control inflammation.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.